Cost effectiveness of quinolones in hospitals and the community

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 71-77

  Davey, Peter ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; COMMUNITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG COST; HOSPITAL; HOSPITAL RUNNING COST; HUMAN; LENGTH OF STAY; ORAL DRUG ADMINISTRATION; TREATMENT FAILURE;

EID: 0032708645     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00014     Document Type: Conference Paper

References (32)

1. Davey PG. Pharmacoeconomics. In: Wilson APR, Gruneberg RN, editors. Ciprofloxacin: 10 years of clinical experience. Oxford: Maxim Medical, 1997: 203-48
2. Davey P, Nathwani D. Sequential antibiotic therapy: the right patient, the right time and the right outcome. J Infection 1998; 37: 37-44
3. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery. A prospective study. Br J Surg 1994; 81: 989-91
4. Grasela TH, Paladino JA, Schentag JJ, et al. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. Ann Pharmacother 1991; 25: 857-62
5. Caceres VM, Stange KC, Kikano GE, et al. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis. J Fam Pract 1994; 39: 337-9
6. Boyter AC, Stephen J, Fegan PG, et al. Why do patients with infection remain in hospital once changed to oral antibiotics? J Antimicrob Chemother 1997; 39: 286-8
7. Jonsson B, Lindgren B. Five common fallacies in estimating the economic gains of early discharge. Soc Sci Med 1990; 14c: 27-33
8. Shepperd S, Harwood D, Gray A, et al. Randomised controlled trial comparing hospital at home care with inpatient care. II: cost minimisation analysis. BMJ 1998; 316: 1791-6
9. Coast J, Richards SH, Peters TJ, et al. Hospital at home or acute hospital care? A cost minimisation analysis. BMJ 1998; 316: 1802-6
10. Parker SE, Nathwani D, O'Reily D, et al. Evaluation of the impact of non-inpatient iv antibiotic treatment for acute infections on the hospital, primary care services and the patient. J Antimicrob Chemother 1998; 42: 373-80
11. Davey PG, Parker SE, Orange G, et al. Prospective audit of costs and outcome of aminoglycoside treatment and of therapy for Gram-negative bacteraemia. J Antimicrob Chemother 1995; 36: 561-75
12. Smith MD, Duong NM, Hoa NTT, et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994; 38 (8): 1716-20
13. Mandell LA, Bergeron MG, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. Can J Infect Dis 1995; 6: 306-15
14. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996; 223: 303-15
15. Cohn SM, Cohn KA, Rafferty MJ, et al. Enteric absorption of ciprofloxacin during the immediate postoperative period. J Antimicrob Chemother 1995; 36: 717-21
16. Adu A, Donovan B, Newgham C, et al. Ciprofloxacin usage in a community hospital. Aust J Hosp Pharm 1994; 24 (4): 318-22
17. Kreling DH, Mott DA. The cost effectiveness of drug utilisation review in an outpatient setting. Pharmacoeconomics 1993; 4: 414-36
18. Partsch DJ, Paladino JA. Cost-effectiveness comparison of sequential ofloxacin versus standard switch therapy. Ann Pharmacother 1997; 31: 1137-45
19. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275: 234-40
20. Isaacs D, Wilkinson AR, Moxon ER. Duration of antibiotic courses for neonates. Arch Dis Child 1987; 62: 727-8
21. Canadian Coordinating Office for Health Technology Assessment. Clinical and economic considerations in the use of fluroquinolones. Canadian Coordinating Office for Health Technology Assessment: 1-12, Dec 1997
22. Grossman R, Mukherjee J, Vaughan D, et al. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113 (1): 131-41
23. Craig A, Malek MM, Davey PG, et al. Economic evaluation with decision analysis: is it useful for medical decision making? The case of acute uncomplicated cystitis in women. Br J Med Econ 1996; 10: 275-90
24. Hooton TM, Winter C, Tiu F, et al. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995; 273: 41-5
25. Hooton TM, Johnson C, Winter C, et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulphamethoxazole for acute cystitis in women. Antimicrob Agents Chemother 1991; 35: 1479-83
26. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065-78
27. Eandi M, Paolo G. Economic impact of resistance in the community. Int J Clin Pract 1998; 95 Suppl.: 27-39
28. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1998; 33: 474-80
29. Sanders CC. ARTs versus ASTs: where are we going? J Antimicrob Chemother 1991; 28: 621-5
30. Walker RD, Thornsberry C. Decrease in antibiotic susceptibility or increase in resistance? J Antimicrob Chemother 1998; 41: 1-4
31. Gallacher G, Erwin L, Scott PJW, et al. Augmentin (amoxycillin-clavulanic acid) compared with amoxycillin alone in the treatment of urinary tract infections in the elderly. J Infect 1986; 12: 229-33
32. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967; 20: 637-48